Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas;Współczesne metody leczenia i monitorowania stanu pacjentów z guzami neuroendokrynnymi przewodu pokarmowego i trzustki

Wspolczesna Onkologia

Volumn 16, Issue 5, 2012, Pages 371-381

  Gut, Paweł ^a   Fischbach, Jakub ^a   Kamiński, Grzegorz ^b   Ruchała, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Uniwersytetu Medycznego   (Poland)

Author keywords

Follow up; Neuroendocrine tumours of the gastrointestinal tract and pancreas; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CELL PROLIFERATION; ENDOCRINE CELL; FOLLOW UP; GASTROINTESTINAL TUMOR; HISTOLOGY; HUMAN; MEDICAL SOCIETY; MITOSIS; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW;

EID: 84870179562     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.31764     Document Type: Review

References (54)

1. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
2. Siddique ZL, Gustaffson BI, Hauso O, et al. The epidemiology of neuroendocrine tumors. In: Nordic and North American Neuroendocrine Tumor Management: a clinical and scientific synopsis 2008. Modlin IM, Oberg KE (eds.). Leopard Communication AB, Stockholm 2008; 170-5.
3. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumours: a consensus propos including a trading system. Virchows Arch 2006; 449: 395-401. (Pubitemid 44451313)
4. Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D i wsp. Zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (rekomendowane przez Polska̧ Sieć Guzów Neuroendokrynnych). Endokrynol Pol 2008; 59: 41-56.
5. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-73. (Pubitemid 39004355)
6. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001; 12 Suppl 2: S111-4. (Pubitemid 33069698)
7. Arnold R, Simon B, WiedM. Treatment of neuroendocrine GEP tumors with somatostatin analogs. Digestion 2000; 62 Suppl 1: 84-91. (Pubitemid 30665945)
8. Maini CL, Sciuto R, Festa A, et al. The role of nuclear medicine in GEP-NET diagnosis and therapy. In: Update in neuroendocrinology. Baldelli R, Casanueva FF, TamburranoG (eds.). Udine Centro UD 2004; 529-44.
9. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002; 14: 38-45. (Pubitemid 34072962)
10. Patel YC, Srikant CB. Subtype selectivity of peptide analogues for all five cloned human somatostatin receptors (hSSTR1-5). Endocrinology 1994; 135: 2814-7. (Pubitemid 24377451)
11. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348-67. (Pubitemid 27410043)
12. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. So - ma tostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005; 80: 502-6. (Pubitemid 40471383)
13. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol 2001; 12 Suppl 2: S105-9. (Pubitemid 33069697)
14. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin analogs. Chemotherapy 2001; 47 Suppl 2: 30-9.
15. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, Lamberts SW. Somatostatin and the immune and haematopoetic system: a review. Eur J Clin Invest 1994; 24: 91-9.
16. Panzuto F, Nansoni S, Corleto VD, et al. Pharmacological treatment of gastroenteropancreatic neuroendocrine tumors. In: Baldelli R, Casanueva FF, Tamburrano G (eds.). Update in neuroendocrinology. Udine Centro UD 2004; 547-61.
17. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-43. (Pubitemid 34081361)
18. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-47. (Pubitemid 29515605)
19. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol 2001; 12: 941-5. (Pubitemid 32725766)
20. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90-YDOTATOC. J Nucl Med 2002; 43: 610-6. (Pubitemid 34507110)
21. Waldeherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90-Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 2002; 29: S100 (abstract).
22. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003; 30: 207-16. (Pubitemid 36686839)
23. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-56. (Pubitemid 43320450)
24. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-82. (Pubitemid 30167697)
25. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octerotate. Eur J Nucl Med Mol Imaging 2003; 30: 417-22. (Pubitemid 36692868)
26. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy and survival. J Clin Oncol 2008; 26: 2124-30.
27. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90YDOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-56.
28. Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ. Treatment of neuroendocrine tumors In adults with 123I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003; 15: 193-8. (Pubitemid 36722765)
29. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA Jr. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004; 101: 1987-93. (Pubitemid 39425373)
30. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 1994; 21: 561-81. (Pubitemid 24189420)
31. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-5.
32. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinoma with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
33. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumours. Cancer 2001; 92: 1101-7. (Pubitemid 32861657)
34. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (Xelox) suitable treatments for progressing low-grade and highgrade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59: 637-42. (Pubitemid 46295128)
35. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
36. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-8.
37. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-95.
38. von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-81. (Pubitemid 32103642)
39. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-23.
40. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-86. (Pubitemid 46595681)
41. Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90: 227-33.
42. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
43. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60: 644-52. (Pubitemid 38669857)
44. Bolanowski M, Jarza̧b B, Handkiewicz-Junak D i wsp. Guzy neuro - endokrynne jelita cienkiego i wyrostka robaczkowego (zasady postȩpowania rekomendowane przez Polska̧ Sieć Guzów Neuro - endokrynnych). Endokrynol Pol 2008; 59: 87-96.
45. Eriksson B, Klöppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuro - endocrinology 2008; 87: 8-19. (Pubitemid 350308290)
46. O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
47. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.
48. Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuro - endocrinology 2009; 90: 184-9.
49. Plöckinger U, Couvelard A, Falconi M, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008; 87: 20-30. (Pubitemid 350308291)
50. Ramage JK, Goretzki PE, Manfredi R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008; 87: 31-9. (Pubitemid 350308292)
51. Van Gompel JJ, Sippel RS, Warner TF, Chen H. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg 2004; 28: 387-92. (Pubitemid 38525873)
52. Kölby L, Bernhardt P, Swärd C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004; 120: 269-73. (Pubitemid 38726216)
53. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211. (Pubitemid 46361054)
54. Nilsson O, Van Cutsem E, Delle Fave G, et al. Poorly differentiated carcinomas of the foregut. Neuroendocrinology 2006; 84: 212-5.